NCT01148979 - Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions

Major Depressive Disorder

Interventions

DRUG

Lisdexamfetamine Dimesylate (Vyvanse)

Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.

DRUG

Placebo

Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.

Trial Locations (1)

McLean Hospital, Belmont